Evaluating pharmaceuticals for health policy and reimbursement:
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Malden, Mass.
BMJ Books/Blackwell Pub.
2004
|
| Schlagworte: | |
| Online-Zugang: | FRO01 UBG01 URL des Erstveröffentlichers |
| Beschreibung: | Includes bibliographical references and index "The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable" So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. Chapters include Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype?; How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings. Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere |
| Beschreibung: | 1 Online-Ressource (ix, 268 pages) |
| ISBN: | 9780470994719 0470994711 1405140976 9781405140973 0727917846 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043386683 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160222s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9780470994719 |9 978-0-470-99471-9 | ||
| 020 | |a 0470994711 |9 0-470-99471-1 | ||
| 020 | |a 1405140976 |9 1-4051-4097-6 | ||
| 020 | |a 9781405140973 |9 978-1-4051-4097-3 | ||
| 020 | |a 0727917846 |9 0-7279-1784-6 | ||
| 024 | 7 | |a 10.1002/9780470994719 |2 doi | |
| 035 | |a (ZDB-35-WIC)ocn181343241 | ||
| 035 | |a (OCoLC)181343241 | ||
| 035 | |a (DE-599)BVBBV043386683 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 362.17/82 |2 22 | |
| 245 | 1 | 0 | |a Evaluating pharmaceuticals for health policy and reimbursement |c edited by Nick Freemantle and Suzanne Hill |
| 264 | 1 | |a Malden, Mass. |b BMJ Books/Blackwell Pub. |c 2004 | |
| 300 | |a 1 Online-Ressource (ix, 268 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a "The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable" So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. Chapters include Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype?; How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings. Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere | ||
| 650 | 4 | |a Drug Evaluation / methods | |
| 650 | 4 | |a Insurance, Pharmaceutical Services / economics | |
| 650 | 4 | |a Cost-Benefit Analysis | |
| 650 | 4 | |a Drug Costs | |
| 650 | 4 | |a Health Policy / economics | |
| 650 | 4 | |a Insurance, Health, Reimbursement / economics | |
| 650 | 7 | |a MEDICAL / Allied Health Services / General |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Pharmaceutical policy | |
| 700 | 1 | |a Freemantle, Nick |e Sonstige |4 oth | |
| 700 | 1 | |a Hill, Suzanne |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028805267 | ||
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719 |l FRO01 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719 |l UBG01 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175956268548096 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043386683 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocn181343241 (OCoLC)181343241 (DE-599)BVBBV043386683 |
| dewey-full | 362.17/82 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.17/82 |
| dewey-search | 362.17/82 |
| dewey-sort | 3362.17 282 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03838nmm a2200553zc 4500</leader><controlfield tag="001">BV043386683</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160222s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470994719</subfield><subfield code="9">978-0-470-99471-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0470994711</subfield><subfield code="9">0-470-99471-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1405140976</subfield><subfield code="9">1-4051-4097-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781405140973</subfield><subfield code="9">978-1-4051-4097-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0727917846</subfield><subfield code="9">0-7279-1784-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/9780470994719</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocn181343241</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)181343241</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043386683</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.17/82</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating pharmaceuticals for health policy and reimbursement</subfield><subfield code="c">edited by Nick Freemantle and Suzanne Hill</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Malden, Mass.</subfield><subfield code="b">BMJ Books/Blackwell Pub.</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (ix, 268 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable" So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. Chapters include Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype?; How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings. Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation / methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance, Pharmaceutical Services / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cost-Benefit Analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Costs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health Policy / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance, Health, Reimbursement / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Allied Health Services / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Freemantle, Nick</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hill, Suzanne</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028805267</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043386683 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:24:31Z |
| institution | BVB |
| isbn | 9780470994719 0470994711 1405140976 9781405140973 0727917846 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028805267 |
| oclc_num | 181343241 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 Online-Ressource (ix, 268 pages) |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | BMJ Books/Blackwell Pub. |
| record_format | marc |
| spelling | Evaluating pharmaceuticals for health policy and reimbursement edited by Nick Freemantle and Suzanne Hill Malden, Mass. BMJ Books/Blackwell Pub. 2004 1 Online-Ressource (ix, 268 pages) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index "The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable" So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. Chapters include Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype?; How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings. Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere Drug Evaluation / methods Insurance, Pharmaceutical Services / economics Cost-Benefit Analysis Drug Costs Health Policy / economics Insurance, Health, Reimbursement / economics MEDICAL / Allied Health Services / General bisacsh Pharmaceutical policy fast Medizin Pharmaceutical policy Freemantle, Nick Sonstige oth Hill, Suzanne Sonstige oth https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Evaluating pharmaceuticals for health policy and reimbursement Drug Evaluation / methods Insurance, Pharmaceutical Services / economics Cost-Benefit Analysis Drug Costs Health Policy / economics Insurance, Health, Reimbursement / economics MEDICAL / Allied Health Services / General bisacsh Pharmaceutical policy fast Medizin Pharmaceutical policy |
| title | Evaluating pharmaceuticals for health policy and reimbursement |
| title_auth | Evaluating pharmaceuticals for health policy and reimbursement |
| title_exact_search | Evaluating pharmaceuticals for health policy and reimbursement |
| title_full | Evaluating pharmaceuticals for health policy and reimbursement edited by Nick Freemantle and Suzanne Hill |
| title_fullStr | Evaluating pharmaceuticals for health policy and reimbursement edited by Nick Freemantle and Suzanne Hill |
| title_full_unstemmed | Evaluating pharmaceuticals for health policy and reimbursement edited by Nick Freemantle and Suzanne Hill |
| title_short | Evaluating pharmaceuticals for health policy and reimbursement |
| title_sort | evaluating pharmaceuticals for health policy and reimbursement |
| topic | Drug Evaluation / methods Insurance, Pharmaceutical Services / economics Cost-Benefit Analysis Drug Costs Health Policy / economics Insurance, Health, Reimbursement / economics MEDICAL / Allied Health Services / General bisacsh Pharmaceutical policy fast Medizin Pharmaceutical policy |
| topic_facet | Drug Evaluation / methods Insurance, Pharmaceutical Services / economics Cost-Benefit Analysis Drug Costs Health Policy / economics Insurance, Health, Reimbursement / economics MEDICAL / Allied Health Services / General Pharmaceutical policy Medizin |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/9780470994719 |
| work_keys_str_mv | AT freemantlenick evaluatingpharmaceuticalsforhealthpolicyandreimbursement AT hillsuzanne evaluatingpharmaceuticalsforhealthpolicyandreimbursement |